Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L‑2‑Amino‑6‑methylene‑pimelic acid is a synthetic, non-proteinogenic amino acid and structural analog of meso-diaminopimelate. It acts as a potent competitive inhibitor of diaminopimelate dehydrogenase, an enzyme involved in the bacterial biosynthesis pathway for meso-diaminopimelate and L‑lysine. This pathway is essential for the growth of certain bacteria but absent in humans, making the enzyme—and its inhibitors—of interest for antibacterial drug development. The compound has been studied primarily as a biochemical probe and experimental tool rather than as a therapeutic agent[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-2-amino-6-methylene-pimelic acid.